$heff's $tation of $tocks & $olid DD

[Stock H.O.G.]

In an almost $2B market with a significant reduction in side effects such as dizziness and somnolence, as well as a more convenient once daily (QD) dosing profile versus the 3-4x daily for generic gabapentin.....if it's not ABT, another biggie will jump on board. DEPO alredy has 2 drugs approved and selling, so it's not their 1st go around here. They also have other drugs in the pipeline, including a significant one in Phase III. This is not a one hit wonder company.